Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Matinas Biopharma Hl (NY: MTNB )

0.4545 +0.0245 (+5.70%)
Official Closing Price Updated: 6:30 PM EDT, Mar 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 350,682
Open 0.4500
Bid (Size) 0.4400 (24)
Ask (Size) 0.4600 (78)
Prev. Close 0.4300
Today's Range 0.4400 - 0.4700
52wk Range 0.3890 - 1.000
Shares Outstanding 217,264,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
Earnings Outlook For Matinas BioPharma Hldgs
 
Via Benzinga

Performance

YTD
-14.73%
-14.73%
1 Month
-6.29%
-6.29%
3 Month
-7.24%
-7.24%
6 Month
-30.08%
-30.08%
1 Year
-44.93%
-44.93%

More News

Read More
Matinas BioPharma: Q2 Earnings Insights
Via Benzinga
Earnings Scheduled For August 11, 2022
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Via Benzinga
Matinas BioPharma Hldgs: Q1 Earnings Insights
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Via Benzinga
A Preview Of Matinas BioPharma Hldgs's Earnings
Via Benzinga
HC Wainwright Reiterates Buy Rating On BioNTech, While Lowers Price Target
Via Benzinga
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines
Via Benzinga
Matinas BioPharma Inks mRNA-Based Vaccine Pact With BioNTech
Via Benzinga
Here's Why Matinas BioPharma Shares Are Rising
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
34 Stocks Moving in Friday's Pre-Market Session
Via Benzinga
Matinas BioPharma Updates — Q4 2021 Earnings And Conference Call Recap
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Via Benzinga
Matinas BioPharma: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For March 8, 2022
Via Benzinga
Earnings Preview For Matinas BioPharma Hldgs
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Exposures Product Safety
51 Biggest Movers From Yesterday
Via Benzinga
22 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.